ABSTRACT
AIMS AND OBJECTIVES: To investigate the effects of Femore™ cream on sexual dysfunction in menopause and women's satisfaction levels. BACKGROUND: The recent interest of public and the world of medicine in female sexual function have led to a rapid increase in the number of studies on the subject. DESIGN: The study was designed as an observational intervention study. METHODS: The research data were collected by using a Women Information Form consisting of 13 items; a Sexual Function Index to measure sexual function; and a Satisfaction Determination Form to determine the level of satisfaction with the medical service the women received for the problems with their reproductive organs. The study was conducted with 29 menopausal women who complied with the inclusion criteria. RESULTS: It was found that women's average age was 52·6; that the average menarche age was 13·0; and that the average menopause age was 46·2. The major complaint of nearly all the women who were aware of their sexual dysfunction was vaginal dryness, and it was concluded that they took no precautions against this problem. The total scores obtained from the Sexual Function Index were reported to be an average of 18·8 ± 4·2 before use of Femore™ cream and an average of 42·3 ± 2·0 after use of Femore™ cream. The average score concerning satisfaction with the use of Femore™ cream was noted to be 9·06 ± 0·40. CONCLUSIONS: The study results suggested that applying Femore™ cream had positive influences on sexual dysfunction and all subdomains. RELEVANCE TO CLINICAL PRACTICE: Women's sexual health can therefore be assessed at primary care centres, and it is considered that health professionals employed at these centres, a majority of whom are female nurses and obstetricians, can play an important role in guiding women on the issue.
